Search results for "Checkpoint Inhibitors"

showing 2 items of 72 documents

Incidence of mucositis during therapy with PD1-PDL1 type immune checkpoint inhibitors

2020

immune checkpoint inhibitorsmucositiscancer
researchProduct

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance

2021

Introduction Immune checkpoint inhibitors (ICIs) are widely used in the treatment of many cancers as they improve clinical outcomes. However, ICIs have also been associated with the development of immune-related adverse drug reactions (ADRs). Among immune-related ADRs, cardiac immune-related ADRs are rare, but also associated with high mortality rates. Objective The objective of this study was to evaluate the occurrence of cardiac ADRs reported with ICIs in the European spontaneous reporting system. Methods We retrieved individual case safety reports on ICI-induced cardiac ADRs from the website of suspected ADR (www.adrreports.eu) of the European pharmacovigilance database (Eudravigilance).…

medicine.medical_specialtyDurvalumabDrug-Related Side Effects and Adverse ReactionsIpilimumabPembrolizumabToxicology030226 pharmacology & pharmacyPharmacovigilance03 medical and health sciences0302 clinical medicineAtezolizumabInternal medicinePharmacovigilancemedicineHumansPharmacology (medical)Original Research Article030212 general & internal medicineMyocardial infarctionImmune Checkpoint InhibitorsPharmacologybusiness.industryOdds ratiomedicine.diseaseIpilimumabNivolumabNivolumabbusinessmedicine.drugDrug Safety
researchProduct